Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-14
2011-06-14
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S206000, C546S205000
Reexamination Certificate
active
07960412
ABSTRACT:
The present invention provides a compound represented by the following formula (I);[wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like;in-line-formulae description="In-line Formulae" end="lead"? (I-1)in-line-formulae description="In-line Formulae" end="tail"?formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Raand Rbare the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.
REFERENCES:
patent: 3274213 (1966-09-01), Lednicer
patent: 4133814 (1979-01-01), Jones et al.
patent: 4418068 (1983-11-01), Jones
patent: 6204286 (2001-03-01), Cameron et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 29 09 754 (1980-09-01), None
patent: 0 226 508 (1987-06-01), None
patent: 0 406 734 (1991-01-01), None
patent: 0 802 183 (1997-10-01), None
patent: 1 199 069 (2002-04-01), None
patent: 3-24069 (1991-02-01), None
patent: WO-01/32631 (2001-05-01), None
patent: WO 02/16316 (2002-02-01), None
Sharp et al., “Synthetic Connections to the Aromatic Directed Metalation Reaction, Functionalized Aryl Boronic Acids by IPSO Borodesilylation, General Synthesis of Unsymmetrical Biphenyls and m-Terphenyls,” Tetrahedron Letters, vol. 28, No. 43, 1987, pp. 5093-5096.
Hamel et al., J. Chem. Soc., Chem. Commun, (16) pp. 1072-1074 (1990).
Reddy et al., Indian Journal of Chemistry, vol. 27B, (16), pp. 563-564 (Jun. 1988).
Loose-Mitchell et al., Goodman and Gilman's, The Pharmaceutical Basis of Therapeutics, 10th Edition, Chapter 58—Estrogens and Progestins, pp. 1597-1634 (2001).
Henderson, Neurology, vol. 48, (5 Suppl 7), pp. S27-S35 (May 1997).
Prince et al., The New England Journal of Medicine, vol. 325, No. 17, pp. 1189-1195 (1991).
Compston, Physicological Reviews, vol. 81, No. 1, pp. 419-447 (2001).
Mendelsohn et al., The New England Journal of Medicine, vol. 340, No. 23, pp. 1801-1811 (1999).
Evans et al., JAMA, vol. 262, No. 18 (1989).
Sherwin, Psychoneuroedocrinology, vol. 13, No. 4, pp. 345-357 (1988).
Duka et al., Psychopharmacology, vol. 149, pp. 129-139 (2000).
Ohkura et al., Endocrine Journal, vol. 41, No. 4, pp. 361-371 (1994).
Henderson, CNS Drugs, vol. 5, No. 8, pp. 343-351 (Nov. 1997).
SCRIP, No. 1812/13, (Apr. 16/20th), p. 31 (1993).
Jordon et al., Breast Cancer Research and Treatment, vol. 10, pp. 31-35 (1987).
Jones et al., J. Med. Chem., vol. 27, pp. 1057-1066 (1984).
Lednicer et al., J. Medicinal Chemistry, vol. 12, No. 5, pp. 881-885 (1969).
Bencze et al., J. Medicinal Chemistry, vol. 10, No. 2, pp. 138-144 (1967).
Lednicer et al., J. Medicinal Chemistry, vol. 10, No. 1, pp. 78-84 (1967).
Hamaoka et al., Drugs Fut, vol. 29 (Suppl A), International Symposium on Medicinal Chemistry, pp. 177-183 (2004).
Yakugaku Zasshi, Journal of the Pharmaceutical Society of Japan, vol. 124, Suppl. 3, p. 183 (2004).
Lombardi et al., Molecular and Cellular Endocrinology, vol. 178, pp. 51-55 (2001).
Barragja et al., Bioorganic & Medicinal Chemistry, vol. 7, pp. 1591-1596 (1999).
Fu et al.: Tetrahedron Letters, vol. 31, No. 12, 1990, pp. 1665-1668, XP002327011.
Boyer et al.: Synthesis, vol. 3, 1978, p. 205, XP002464895.
Wittig et al.: vol. 91, 1958, pp. 2358-2365. XP002464896.
Gopinath et al: Journal of the Chemical Society, No. 1958, 1958, pp. 504-509. XP002099088.
Littleton-Kearney et al., “Selective Estrogen Receptor Modulators: Tissue Actions and Potential for CNS Protection”, CNS Drug Reviews, vol. 8, No. 3, pp. 309-330, 2002.
Ettinger et al., “Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene”, JAMA, Aug. 18, 1999, vol. 282, No. 7, pp. 637-645.
Walsh et al., “Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women”, JAMA, May 13, 1998, vol. 279, No. 18, pp. 1445-1451.
Labrie et al., “EM-652 (SCH57068), a pure SERM having Complete Antiestrogenic Activity in the Mammary Gland and Endometrium”, Journal of Steroid Biochemistry & Molecular Biology 79, 2000, pp. 213-225.
Walsh et al., “The Effects of Hormone Replacement Therapy and Raloxifene on C-Reactive Protein and Homocysteine in Healthy Postmenopausal Women: A Randomized, Controlled Trial”, The Journal of Clinical Endocrinology & Metabolism, vol. 85, No. 1,. pp. 214-218, 2000.
Cummings et al., “The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results from the MORE Randomized Trial”, JAMA, Jun. 16, 1999, vol. 281, No. 23, pp. 2189-2197.
Gottardis et al., “Effect of Steroidal and Nonsteroidal Antiestrogens on the Growth of a Tamoxifen-stimulated Human Endometiral Carcinoma (EnCa101) in Athymic Mice”, Cancer Research 50, Jun. 1, 1990, pp. 3189-3192.
ACOG practice bulletin, “Selective Estrogen Receptor Modulators”, International Journal of Gynecology & Obstetrics 79, 2002, pp. 289-298.
Neven et al., “The Effect of Raloxifene on the Incidence of Ovarian Cancer in Postmenopausal Women”, Gynecologic Oncology 85, 2002, pp. 388-390.
Pearce et al., “Psychological and Sexual Aspects of the Menopause and HRT”, Bailliere's Clinical Obstetrics and Gynaecology, vol. 10, No. 3, Sep. 1996, pp. 385-399.
Phillips et al., “Muscle Weakness in Women Occurs at an Earlier Age than in Men, but Strength is Preserved by Hormone Replacement Therapy”, Clinical Science, 1993, 84, pp. 95-98.
Database Beilstein [online], “Beilstein Institute for Organic Chemistry”, Frankfurt-Main, DE; Database accession No. 173027 (Feb. 2010).
Database Beilstein [online], “Beilstein Institute for Organic Chemistry”, Frankfurt-Main, DE; Database accession No. 2109126 (Feb. 2010).
Database Beilstein [online], “Beilstein Institute for Organic Chemistry”, Frankfurt-Main, DE; Database accession No. 8619569 (Feb. 2010).
Nicolaus, “Symbiotic Approach to Drug Design”, Decision Making in Drug Research, Jan. 1, 1983, pp. 173-186, XP001111439.
Office Action dated Jul. 21, 2010 for European Application No. 03782904.1.
Office Action dated Dec. 10, 2009 for Japanese Application No. 2004-562947.
Office Action dated Jan. 9, 2007 for Austrialian Application No. 2003292625.
Office Action dated Nov. 18, 2008 for Candian Application No. 2512000.
Hamaoka Shinichi
Kamada Atsushi
Kitazawa Noritaka
Nara Kazumasa
Okabe Tadashi
Aulakh Charanjit S
Birch & Stewart Kolasch & Birch, LLP
EISAI R&D Management Co., Ltd.
LandOfFree
Selective estrogen receptor modulator does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective estrogen receptor modulator, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective estrogen receptor modulator will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2681243